Abstract
AbstractSeven viruses cause at least 15% of the total cancer burden. Viral cancers have been described as the “low-hanging fruit” that can be potentially prevented or treated by new vaccines that would alter the course of global human cancer. Kaposi sarcoma herpesvirus (KSHV or HHV8) is the sole cause of Kaposi sarcoma, which primarily afflicts resource-poor and socially marginalized populations. This review summarizes a recent NIH-sponsored workshop’s findings on the epidemiology and biology of KSHV as an overlooked but potentially vaccine-preventable infection. The unique epidemiology of this virus provides opportunities to prevent its cancers if an effective, inexpensive, and well-tolerated vaccine can be developed and delivered.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference134 articles.
1. Aelion, C. M. et al. The US Cancer Moonshot initiative. Lancet Oncol. 17, e178–e180 (2016).
2. de Martel, C., Georges, D., Bray, F., Ferlay, J. & Clifford, G. M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health 8, e180–e190 (2020).
3. Lei, J. et al. HPV vaccination and the risk of invasive cervical cancer. N. Engl. J. Med. 383, 1340–1348 (2020).
4. Li, C. & He, W. Q. The impact of universal hepatitis B vaccine on the trend of liver cancer from the Global Burden of Disease Study 2017. Liver Int. 41, 1762–1774 (2021).
5. Chang, Y., Gao, S.-J. & Moore, P. S. In Clinical Virology (eds Richman, D. D., Whitley, R. J., Hayden, F. G.) 549–574 (ASM Press, 2016).
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献